Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Top Cited Papers
- 24 April 2017
- journal article
- Published by Springer Science and Business Media LLC in Nature Chemical Biology
- Vol. 13 (6), 675-680
- https://doi.org/10.1038/nchembio.2363
Abstract
Target-protein degradation is an emerging field in drug discovery and development. In particular, the substrate-receptor proteins of the cullin-ubiquitin ligase system play a key role in selective protein degradation, which is an essential component of the anti-myeloma activity of immunomodulatory drugs (IMiDs), such as lenalidomide. Here, we demonstrate that a series of anticancer sulfonamides NSC 719239 (E7820), indisulam, and NSC 339004 (chloroquinoxaline sulfonamide, CQS) induce proteasomal degradation of the U2AF-related splicing factor coactivator of activating protein-1 and estrogen receptors (CAPERα) via CRL4 mediated ubiquitination in human cancer cell lines. Both CRISPR-Cas9-based knockout of DCAF15 and a single amino acid substitution of CAPERα conferred resistance against sulfonamide-induced CAPERα degradation and cell-growth inhibition. Thus, these sulfonamides represent selective chemical probes for disrupting CAPERα function and designate DCAFs as promising drug targets for promoting selective protein degradation in cancer therapy.Keywords
This publication has 44 references indexed in Scilit:
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligaseNature, 2016
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSNature, 2015
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Cell Chemical Biology, 2015
- CAPER Is Vital for Energy and Redox Homeostasis by Integrating Glucose-Induced Mitochondrial Functions via ERR-α-Gabpa and Stress-Induced Adaptive Responses via NF-κB-cMYCPLoS Genetics, 2015
- CAPER‐α alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cellsCancer, 2011
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future PerspectivesCurrent Cancer Drug Targets, 2011
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancerNature, 2009
- DCAFs, the Missing Link of the CUL4-DDB1 Ubiquitin LigaseMolecular Cell, 2007
- A Family of Diverse Cul4-Ddb1-Interacting Proteins Includes Cdt2, which Is Required for S Phase Destruction of the Replication Factor Cdt1Molecular Cell, 2006
- Molecular Cloning and Characterization of CAPER, a Novel Coactivator of Activating Protein-1 and Estrogen ReceptorsJournal of Biological Chemistry, 2002